NCT00017693View on ClinicalTrials.gov

Recombinant Human IL-4 Receptor Used in Treatment of Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

May 31, 1998

Primary Completion Date

February 29, 2000

Study Completion Date

February 29, 2000

Conditions
Asthma
Interventions
BIOLOGICAL

Recombinant human soluble IL-4 receptor

Subjects were randomized to twelve once weekly nebulizations of 0.75, 1.5, or 3.0 mg dose of recombinant human soluble IL-4 receptor (rsIL-4R)

BIOLOGICAL

Placebo for Recombinant human soluble IL-4 receptor

Subjects were randomized to twelve once weekly nebulizations of placebo for recombinant human soluble IL-4 receptor (rsIL-4R). Identically prepared (to the recombinant human soluble IL-4 receptor) in the same volume

Sponsors

Collaborators (1)

Immunex Corporation
All Listed Sponsors
collaborator

Immunex Corporation

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH